진행성 비소세포성 폐암환자에 대한 항암플러스의 치료효능: 연속증례보고
Case Series of Advanced Non-Small Cell Lung Cancer Patients Treated with Hang-Am Plus
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Objectives : A case series was conducted to investigate the therapeutic effects of Hang-Am Plus (HAP) on the tumor response and HRQoL (Health Related Quality of Life) in advanced non-small cell lung cancer (NSCLC) patients. Methods : Three patients were given 1,000-2,000 ㎎ of HAP, three times a day (daily total dosage of 3,000-6,000 ㎎/day) for 12 weeks. Results : After the 3 month administration with HAP, three patients showed stable disease (SD) condition according to the chest computed tomography (CT), and two of the patients reported a decrease in pain levels. Conclusions : The observed NSCLC cases suggest treatment with HAP may be related to the observed tumor growth inhibition and pain reduction.
Abstract
Objectives : A case series was conducted to investigate the therapeutic effects of Hang-Am Plus (HAP) on the tumor response and HRQoL (Health Related Quality of Life) in advanced non-small cell lung cancer (NSCLC) patients. Methods : Three patients were given 1,000-2,000 ㎎ of HAP, three times a day (daily total dosage of 3,000-6,000 ㎎/day) for 12 weeks. Results : After the 3 month administration with HAP, three patients showed stable disease (SD) condition according to the chest computed tomography (CT), and two of the patients reported a decrease in pain levels. Conclusions : The observed NSCLC cases suggest treatment with HAP may be related to the observed tumor growth inhibition and pain reduction.
참고문헌 (23)
- , 국가암정보센터 암발생률, 암종별 발생 현황[URL]
- Jemal A, "Cancer statistics", CA Cancer J Clin, 60(5), pp.277~300 (2010)
- Hayat MJ, "Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program", Oncologist, 12, pp.20~37 (2007)
- Asamura H, "How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations", J Thorac Cardiovasc Surg, 132, pp.316~319 (2006)
- Herbst RS, "Lung cancer", N Engl J Med, 359(13), pp.1367~1380 (2008)
- Schiller JH, "Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346(2), pp.92~98 (2002)
- 查名宝, "参麦注射液合并化疗治疗非小细胞性肺癌的临床观察", ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL, 10(6), pp.724~728 (2006)
- 유승후, "항암단을 투여한 재발성 편평상피폐암 환자에 대한 7년간의 추적조사", 대한한방내과학회지, 28(2), pp.387~392 (2007), 대한한방내과학회
- YANG YW, "Lung Cancer and Traditional Chinese Medicine Therapy", CHINESE ARCHIVES OF TRADITIONAL CHINESE MEDICINE, 27(9), pp.1934~1936 (2009)
- 周雍明, "肺瘤平膏改善非小细胞肺癌患者免疫状态及预后的临床观察", Chinese Journal of Information on TCM, 15(5), pp.78~79 (2008)
- 贾英杰, "Clinical observation on advanced non-small cell carcinoma of lung treated by Xiaoyan decoction", TIANJIN JOURNAL OF TRADITIONAL CHINESE MEDICINE, 21(2), pp.108~109 (2004)
- 김경순, "항암플러스 투여로 호전된 진행성 비소세포성 폐암 연속환자증례", 대한한방내과학회지, 30(4), pp.893~900 (2009), 대한한방내과학회
- MENG ZQ, "Phase Ⅰ study of huachansu in hepatocellular carcinoma, non-small cell lung cancer, and pancreatoc cancer: a preliminary report", CHINA ONCOLOGY, 17(5), pp.376~379 (2007)
- Deng J, "Clinical observations of cinobufotalin combined with gefitinib for advanced non-small cell lung cancer patients", CHINESE JOURNAL OF MODERN DRUG APPLICATION, 1(11), pp.29~30 (2007)
- Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350(21), pp.2129~2139 (2004)
- Herbst RS, "Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab", Oncologist, 9(1), pp.19~26 (2004)
- Gridelli C, "Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer", The Oncologist, 12(2), pp.191~200 (2007)
- 이동은, "항암단 및 그 주요 성분의 Calu6 와 MCF-7 사람 암세포주에 대한 항암효과", 대한한의학회지, 30(5), pp.50~60 (2009), 대한한의학회
- 李大鹏, "康莱特注射液抗癌作用激励研究进展", Traditional Chinese Drug Research & Clinical Pharmacology, 12(2), pp.122~124 (2001)
- Park SC, "Induction of apoptosis in human lung carcinoma cells by the water extract of Panax notoginseng is associated with the activation of caspase-3 through downregulation of Akt", International Journal of Oncology, 35(1), pp.121~127 (2009), Demetrios A. Spandidos Ed. & Pub.
- Park SE, "Induction of apoptosis and inhibition of telomerase activity in human lung carcinoma cells by the water extract of Cordyceps militaris", FOOD AND CHEMICAL TOXICOLOGY, 47(7), pp.1667~1675 (2009), PERGAMON-ELSEVIER SCIENCE LTD
- 방지영, "Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip", BioChip Journal, 4(4), pp.350~355 (2010), 한국바이오칩학회
- 유화승, "A Toxicological Study of HangAmDan-B in Mice", Journal of Acupuncture & Meridian Studies, 4(1), pp.54~60 (2011), 사단법인약침학회